New drug combo aims to shrink liver tumors in colorectal cancer patients

NCT ID NCT07082439

Recruiting now Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether a combination of two drugs, pembrolizumab and odetiglucan, can safely shrink tumors in people with colorectal cancer that has spread mainly to the liver. About 27 participants will receive the drugs every three weeks. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab and odetiglucan
What this could lead to: If this combination works, it could offer a new treatment option for people with colorectal cancer that has spread mostly to the liver, potentially shrinking tumors and slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The drugs may cause side effects, and there is no guarantee the combination will be more effective than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA METASTATIC IN THE LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL ADENOCARCINOMA METASTATIC IN THE LIVER

Contacts and locations

Locations

Abramson Cancer Center at the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.